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Abstract
Background: Transcription factor 7-like 2 (TCF7L2) has been shown to be associated with type 2
diabetes mellitus (T2MD) in multiple ethnic groups in the past two years, but, contradictory results
were reported for Chinese and Pima Indian populations. The authors then performed a large meta-
analysis of 36 studies examining the association of type 2 diabetes mellitus (T2DM) with
polymorphisms in the TCF7L2 gene in various ethnicities, containing rs7903146 C-to-T (IVS3C>T),
rs7901695 T-to-C (IVS3T>C), a rs12255372 G-to-T (IVS4G>T), and rs11196205 G-to-C
(IVS4G>C) polymorphisms and to evaluate the size of gene effect and the possible genetic mode
of action.
Methods: Literature-based searching was conducted to collect data and three methods, that is,
fixed-effects, random-effects and Bayesian multivariate mete-analysis, were performed to pool the
odds ratio (OR). Publication bias and study-between heterogeneity were also examined.
Results: The studies included 35,843 cases of T2DM and 39,123 controls, using mainly primary
data. For T2DM and IVS3C>T polymorphism, the Bayesian OR for TT homozygotes and TC
heterozygotes versus CC homozygote was 1.968 (95% credible interval (CrI): 1.790, 2.157), 1.406
(95% CrI: 1.341, 1.476), respectively, and the population attributable risk (PAR) for the TT/TC
genotypes of this variant is 16.9% for overall. For T2DM and IVS4G>T polymorphism, TT
homozygotes and TG heterozygotes versus GG homozygote was 1.885 (95%CrI: 1.698, 2.088),
1.360 (95% CrI: 1.291, 1.433), respectively. Four ORs among these two polymorphisms all yielded
significant between-study heterogeneity (P < 0.05) and the main source of heterogeneity was ethnic
differences. Data also showed significant associations between T2DM and the other two
polymorphisms, but with low heterogeneity (P > 0.10). Pooled ORs fit a codominant, multiplicative
genetic model for all the four polymorphisms of TCF7L2 gene, and this model was also confirmed
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in different ethnic populations when stratification of IVS3C>T and IVS4G>T polymorphisms except
for Africans, where a dominant, additive genetic mode is suggested for IVS3C>T polymorphism.
Conclusion: This meta-analysis demonstrates that four variants of TCF7L2 gene are all associated
with T2DM, and indicates a multiplicative genetic model for all the four polymorphisms, as well as
suggests the TCF7L2  gene involved in near 1/5 of all T2MD. Potential gene-gene and gene-
environmental interactions by which common variants in the TCF7L2 gene influence the risk of
T2MD need further exploration.
Background
Type 2 diabetes mellitus (T2DM) is characterized by
hyperglycemia that can occur through mechanisms such
as impaired insulin secretion, insulin resistance in periph-
eral tissues and increased glucose output by liver [1]. Most
individuals with T2DM suffer serious complications of
chronic hyperglycemia, involved in nephropathy, neurop-
athy, retinopathy, and accelerated development of cardio-
vascular disease [2]. The prevalence of T2DM has
increased sharply during the past two decades in the world
and is close to 6% [3]. But estimations suggest that this
trend will continue to rise over the next decade owing to
increasing age of population and surge of obesity [4].
Accounting for 90~95% of populations with diabetes,
T2DM is projected to 300 million worldwide by year 2025
[2,4], and its incidence exhibits significant geographic and
racial difference, ranging from more than 0.3 to 17.9% in
Africa [5-11], 1.2 to 14.6% in Asia [12-19], about 2.5% in
Australia [20], 0.7 to 11.6% in Europe [21-32], 4.6 to 40%
in the Middle East [33-36], 6.69 to 28.2% in North Amer-
ica [3,37-39], and 2.01 to 17.4% in South America [40-
43]. Recent years, new diagnosis of T2DM subjects in
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developing nations with a mass of populations such as
China and India has increased rapidly [19,44,45], and it
has also found remarkable augmented in rural that being
with lower prevalence before [14,17,19,45]. Incidence
rates are diverse in females and males in Europe, North
America, Africa, Latin America and East Asia, and there are
scarcely reports with accordant result.
Transcription factor 7-like 2 (TCF7L2) gene spans a
215,863 bases region on chromosome 10q25.3 [46]
(114700201–114916063, NCBI build 36.2), and its prod-
uct is a high-mobility box-containing transcription factor
that has a role in activating many genes downstream of
the Wnt signaling pathway and in T2DM [47-50]. The
mechanisms through which TCF7L2 affects the suscepti-
bility to T2DM remain to be elucidated. The bipartite tran-
scription factor, cat/TCF7L2, activates many genes
downstream of the Wnt signaling cascade [51]. One of the
genes transcriptionally regulated by cat/TCF7L2 is proglu-
cagon, which encodes the insulinotropic hormone gluca-
gon-like peptide 1 (GLP-1) [49,50]. Because GLP1, in
concert with insulin, plays a critical role in blood glucose
homeostasis, it has been postulated that TCF7L2 gene var-
iants may affect the susceptibility to type2 diabetes by
indirectly altering GLP-1 levels [50].
The human TCF7L2  gene consists of 14 exons and 13
introns (NCBI build 36.2). However, a previous study
[52] has shown that TCF7L2 has 17 exons, of which five
are alternative. There are at least four well-studied poly-
morphic markers that have brought the most attention,
that is, (1) a C-to-T (genomic position: 114748339) sub-
stitution at snp rs7903146 of the intron 3 (IVS3C>T)
[2,47,53,54]; (2) a T-to-C (genomic position:
114744078) substitution at snp rs7901695 of the intron
3(IVS3T>C) [2,53,55]; (3) a G-to-T (genomic position:
14798892) substitution at snp rs12255372 of the intron
4 (IVS4G>T) [2,56]; and (4) a G-to-C (genomic position:
114797037)substitution at snp rs11196205 of the intron
4 (IVS4G>C) [57,58]. Most published epidemiologic
studies have emphasized on the IVS3C>T and IVS4G>T
polymorphisms [2,47,59-65]. There are plenty of evi-
dence on strong linkage disequilibrium between these
four polymorphisms [2,47,57,58]. The T allele of the
IVS3C>T, C allele of the IVS3T>C, and T allele of IVS4G>T,
as well as C allele of IVS4G>C polymorphisms have
Funnel plots of rs7903146 polymorphism studies for T homozygotes vs. C homozygotes (corrected z = 0.02, corrected P =  0.987) Figure 2
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higher frequency in Caucasian [59,66], North European
[2,47], African [67,68], and Indian [69,70] populations
than those in East Asian [57,61,62,71] populations.
The polygenic basis of T2DM has been intensely investi-
gated by large consortia worldwide, and consensus on a
range of valid susceptibility genes has emerged. Such
genes, for example PPARG, KCNJ11 and CPN10, appear to
contain common variation that confers only 10–20%
additional risk of T2DM, and only studies with large num-
bers of case and controls have had sufficient statistical
power to examine their role robustly [72]. Recent years,
some novel loci in genes such as TCF7L2,  SLC30A8,
HHEX,  ETX2,  CDKN2A/CDKN2B,  IGF2BP2,  CDKAL1,
FTO, PPARG, and KCNJ11 have been found with suscep-
tibility to T2DM [2,73-76], and these has promoted the
development of genetics on T2DM. From 2006 to 2008,
study on TCF7L2 gene polymorphisms and its association
with T2DM has become the focus in diabetes mellitus,
therefore, some meaningful results have reported one by
one. In March, 2006, Grant and colleagues [2] first pro-
posed an association with TCF7L2  gene variants with
T2DM. The study [2] consisted of three samples from Ice-
land, Denmark and USA with strikingly similar results.
Since then, this potential association has been examined
in over 50 samples from around the world. Given the
amount of accumulated data, it is important and urgent to
perform a quantitative synthesis of these evidences. We
therefore undertake a large meta-analysis of studies of the
association between TCF7L2  gene polymorphisms and
T2DM. To exclude heterogeneity of these studies, we strat-
ified the data by Hardy-Weinberg equilibrium (HWE),
publishing time, ethnicity, body mass index (BMI), diag-
nosis and age.
Although one meta-analysis [77] and several narrative
reviews about TCF7L2 gene and T2DM had been reported
[78-80], Succedent studies have now made more data
available. Compared with the only one meta-analysis
written by Cauchi and his colleagues [77] and published
online in May, 2007, 28 more studies from 14 new papers
[53,55,57,63,68,69,71,73-76,81-83]were available to us.
And that, this meta-analysis of the association between
TCF7L2 gene and T2DM, only summarized IVS3C>T pol-
ymorphism by just analyze allele frequency [77], the
authors did not generalize the association between other
Funnel plots of rs7903146 polymorphism studies for heterozygotes vs. C homozygotes (corrected z = 0.80, corrected P =  0.426) Figure 3
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important variations such as IVS4G>T, IVS3T>C and
IVS4G>C polymorphisms and T2DM. Further, the only
meta-analysis was based on published data, namely, with-
out stratification, and, was thus limited in the interpreta-
tions they allowed. However, using the original data, we
are able to explore more deeply, searching for sources of
heterogeneity. Thus, we carried out a large meta-analysis
to conduct a broad comprehensive and quantitative
assessment on the association between variants of TCF7L2
gene and T2DM, and then, to perform a detailed examina-
tion of sources of heterogeneity. We sought to estimate
magnitude of the genetic association as well as the genetic
mode of action, and to determine the extent of heteroge-
neity in the strength of associations between different
studies.
Methods
Search strategy and inclusion criteria
We conducted a comprehensive search of the US National
Library of Medicine's PubMed, OMIM, ISI Web of Science,
and Embase databases for all genetic association studies
on at least one of the above four polymorphisms in the
TCF7L2 gene and T2DM published from March, 2006,
when the association between TCF7L2 gene and T2DM
was first reported [2], through March, 2008. The search
strategy was based on combination of the key words "tran-
scription factor 7-like 2" or "TCF7L2" or "TCF7L2 gene
polymorphism", and "diabetes" or "diabetes 2" or "type 2
diabetes" or "type 2 diabetes mellitus" or "T2D" or
"T2DM". The references of all computer-identified publi-
cations were searched for additional studies, and the
PubMed option "Related Articles" was used to search for
potentially relevant papers. Reference lists in retrieved
articles were also screened.
Searching was performed in duplicate by two independ-
ent reviewers (YZ and JYY). Without any language restric-
tion (we will translate articles published in other
languages into English by professional interpreters), we
only selected published manuscripts (including their
online supporting materials and the original data kindly
sent by the authors) if they met the following criteria: 1)
the publication was a population-based association study
(family-based study design with linkage considerations
was excluded), regardless of sample size, and 2) there
were enough results for extraction of data, that is, the
Cumulative meta-analysis of the odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for T  allele vs. C allele Figure 4
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number of subjects with each allele and genotype in the
T2DM and control groups. Where eligible papers had
insufficient information, we contacted authors by e-mail
or mail for additional information. In the case of sequen-
tial or multiple publications of analyses of the same data
or overlapping data sets, the publication that reported
data from the largest or most recent study was included.
Data extraction
Data were extracted independently and in duplicate by
two investigators (YZ and JJY) who used the recom-
mended guidelines for reporting on meta-analyses of
observational studies [84]. The following data were
extracted from the eligible studies: authors, journal and
year of publication, country of origin, selection and char-
acteristics of cases and controls, demographic data, eth-
nicity of the study population (Caucasian, North
European, East Asian, African, Middle Eastern, American,
or Pacific Asian), numbers of eligible and genotyped cases
and controls, and genotype distributions in cases and con-
trols and available subgroups thereof. Furthermore, we
examined whether matching had been used; whether
there was specific mention of blinding of the genotyping
personnel to the clinical status of subjects; whether the
genotyping method used had been validated; and whether
genotype frequencies in control groups were in HWE. Any
disagreement was adjudicated by a third author (YWZ).
Statistical Analysis
We used the odds ratio as the metric of choice and it was
estimated for each study. In order to explore the possible
association between TCF7L2  gene polymorphisms and
T2MD and to avoid excessive comparisons, we calculated
the odds ratio by two methods, namely, allele comparison
(i.e., T allele vs. C allele in IVS3C>T polymorphism), and
genotype comparison, that is, comparing the risk variant
homozygotes and heterozygotes with wild homozygotes,
respectively (i.e., TT vs. CC (OR1) and TC vs. CC (OR2) in
IVS3C>T polymorphism; TT vs. GG (OR3) and TG vs. GG
(OR4) in IVS4G>T polymorphism; CC vs. TT (OR5) and
CT vs. TT (OR6) in IVS3T>C polymorphism; CC vs. TT
(OR7) and CT vs. TT (OR8) in IVS4G>C polymorphism).
We estimated and characterized the summary prevalence
of risk allele by using only the data on controls. When we
analyze genotype data for meta-analysis, cells with zero
count had 0.5 been added. In addition, we calculated the
Cumulative meta-analysis of the odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for T  homozygotes vs. C homozygotes Figure 5
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population attributable risk (PAR) of risk allele according
to method of Chang et al [71].
We first compared alleles for cases and controls in order to
detect overall differences and genetic association. Allele
frequencies were computed for studies reporting only gen-
otypic data. Pooled odds ratio were computed three times,
by the fixed-effects method of Mantel and Haenszel [85],
by the random-effects method of DerSimonian and Laird
[86], and by the Bayesian random-effects method of Warn
et al [87]. Unless stated otherwise, random-effects esti-
mates (DerSimonian and Laird) are reported here.
Our primary analysis for TCF7L2  gene polymorphisms
and T2DM is based on genotype comparisons in order
that magnitude of the genetic association and the genetic
mode of action can be identified exactly. Once an overall
gene effect was confirmed by the allele comparison, the
genotype effects and genetic model were estimated by
using the genetic model-free approach suggested by
Minelli et al [88], where no assumptions about genetic
models were required. The OR1 to OR8 were calculated by
using multivariate meta-analysis with Bayesian method
[88]. The logarithm (log) odds ratios were modeled on
the base of both between and within study variations.
Four separate stochastic lambda values (reflecting the
genetic model), consisting of the ratios of logOR2 versus
logOR1 for λ1, logOR4 versus logOR3 for λ2, logOR6 versus
logOR5 for λ3, and logOR8 versus logOR7 for λ4, were cal-
culated [88]. The parameter λ capture information about
the genetic mode of action, briefly, the model is a reces-
sive model if λ = 0, a codominant model if λ = 0.5, a dom-
inant model if λ = 1, and homozygous or heterosis model
if λ < 0 or λ > 1. Pooled odds ratio were also computed by
the fixed-effects method of Mantel and Haenszel [85] and
by the random-effects method of DerSimonian and Laird
[86]. Unless stated otherwise, Bayesian estimates are
reported here.
We tested for deviations from Hard-Weinberg equilib-
rium (HWE) in both case and control populations by
using the exact method reported by Emigh et al [89]
whether the author provide the P values of HWE or not.
For above allele-based and genotype-base analyses, we
Cumulative meta-analysis of the odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for  heterozygotes vs. C homozygotes Figure 6
Cumulative meta-analysis of the odds ratios of association between rs7903146 polymorphism of TCF7L2 gene 
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took two methods to handle Hard-Weinberg disequilib-
rium. Firstly, we performed sensitivity analyses by includ-
ing by including and excluding studies in Hard-Weinberg
disequilibrium (case and control group were all consid-
ered). Secondly, we included all studies regardless of HWE
and instead adjusted for the degree of disequilibrium by
using the inbreeding coefficient (F) suggested by Trika-
linos et al [90]. Briefly, the F was estimated for each study
by using data in the control group. Predicted genotype fre-
quencies were estimated [91] and used instead of the
observed frequencies in the summary analysis of magni-
tude and genetic model.
In sensitivity analysis, we estimated between-study heter-
ogeneity across all eligible comparisons using Cochran's
Q statistic [92]. Heterogeneity was considered significant
at P value less than 0.10 [92]. We also report I2 statistic,
which describes the percentage of variability in point esti-
mates due to sample heterogeneity rather than sampling
error [93,94], and can quantify heterogeneity irrespective
of the number of studies [94,95]. As a guide, I2 values less
than 25 percent may be considered "low", values of 31
percent to 56 percent have been defined as indicating
"low" to "moderate" heterogeneity, whereas values greater
than 56 percent are considered indicative of "notable"
heterogeneity, and "large" heterogeneity is stipulated for
I2 values of larger than or equal to 75 percent [94,95]. The
examination of heterogeneity was performed separately
for two odds ratios (OR1 and OR2 for IVS3C>T polymor-
phism,  OR3 and OR4 for IVS4G>T polymorphism, OR6
and OR7 for IVS3T>C polymorphism, OR7 and OR8 for
IVS4G>C polymorphism) in genotype-based analysis. If
there was heterogeneity on at least one of these two odds
ratios, the source of the heterogeneity was explored by fit-
ting a covariable (such as age, gender, ethnicity, BMI) in a
meta-regression model [96-98]. Possible subgroup analy-
ses were involved in ethnicity (Caucasians, North Europe-
ans, East Asians, Indians and other racial groups), age (<
65 years vs. ≥ 65 years), diagnosis (normal diagnosis vs.
no diagnosis or false diagnosis), publishing time (2006
vs. 2007 and 2008) and BMI (normal (< 30.0 kg/m2) vs.
abnormal (≥ 30.0 kg/m2) according to the meta-regres-
sion analysis. Logistic regression analysis was used to
compare odds ratios among these possible groups. In
Odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for T allele vs. C allele Figure 7
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addition, genetic association studies may be especially
susceptibility to the selective publication of positive find-
ings on gene association [99]. In order to investigate the
publication bias among studies, funnel plots [100] and
cumulative meta-analysis [101] were used.
All analyses were conducted in Stata software, version 9.0
[102], using meta, metan, metabias, metacum, and metareg
commands, except for the Bayesian method of genotype-
based analysis. We fit the Bayesian models by using
Markov chain Monte Carlo (MCMC) methods with Baye-
sian framework and perform our inferences using Win-
BUGS 1.4.3 [103], taking advantage of its flexibility as
well as its ability to incorporate full uncertainty in all
unknown parameters. Bayesian analyses yield credible
intervals rather than confidence intervals; a 95% credible
interval (CrI) describes a range in which the probability
that the unknown quantity lies within this interval, after
seeing the data, is 95%. A 'burn-in' of 10,000 iterations is
carried out for models, followed by 50,000 iterations for
parameter estimates. A P value less than 0.05 was consid-
ered statistically significant, except for tests of heterogene-
ity, where a level of 0.10 was used.
Results
Eligible studies
Totally eighty-nine papers were identified across Medline
and Embase on the base of our search strategies. Two of
the studies [57,71]did not have genotypic data, but the
authors friendly sent the supplementary information to
us. Parra et al [68], reported four samples, that is, two
Mexican American populations, one Spanish and one
Nigerian population. With no controls of last three popu-
lations, we combined the two Mexican samples and then,
discarded the Spanish and Nigerian samples in meta-anal-
ysis of polymorphism of IVS3C>T and IVS4G>T. There-
fore, 25 eligible papers [2,53,55-71,74,75,77,81-83],
including 36 studies (multiple studies performed in one
paper in particular: 3 studies in paper of Grant et al [2],
Horikoshi et al [62], Humphries et al [67], and Miyake et
al [82]; 2 studies in paper of Scott et al [74], Sladek et al
[75], and Cauchi et al [77]), examining the association
Odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for T homozygotes vs. C homozy- gotes Figure 8
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between TCF7L2 gene polymorphisms and T2DM were
identified by the inclusion criteria and all of them were
written in English (Table 1, Additional file 1). The eligible
studies for analysis involved in a total of 35,843 cases with
T2DM and 39,123 controls. 35 studies from 24 papers
[2,53,55,57-71,74,75,77,81-83] contained data for the
IVS3C>T polymorphism (Table 2, Additional file 1), 10
studies from 8 papers contained data for the IVS3T>C pol-
ymorphism (Table 3, Additional file 1), 21 papers
involved in 29 studies contained data for the IVS4G>T
polymorphism (Table 4, Additional file 1), and 9 papers
including 15 samples contained data for IVS4G>C poly-
morphism (Table 5, Additional file 1).
There was considerable diversity of ethnic groups. Eligibil-
ity criteria for T2DM patients were shown in Table 1
(Additional file 1). Controls were mainly healthy popula-
tions who were described as nondiabetic and/or, Normo-
glycemic, and/or normal glucose tolerance (NGT),
although varying details were presented regarding the
extent of testing that had been done to excluded controls
with impaired glucose tolerance and diabetes (table 1,
Additional file 1). Remaining 3 investigations did not
report the details of controls [60,66,67]. 1 study matched
for geographic region [53]; 1 study matched for age, race,
and BMI [56]; 5 studies matched for race [55,67,70,83];
and one study 1 study matched for age, sex, and geo-
graphic region [58,65]. The other investigations did not
provide for the details of the matching information.
Detailed characteristics of each investigation, along with P
values for testing HWE, are listed in the Table 2–5 (Addi-
onal file 1) for IVS3C>T polymorphism, IVS3T>C poly-
morphism, IVS4G>T polymorphism and IVS4G>C
polymorphism, respectively.
IVS3C>T polymorphism
The eligible studies for analysis of IVS3C>T polymor-
phism included a total of 33,135 cases with T2DM and
36,316 controls (Table 2, Additional file 1). Allele and
genotype data were available for all the cases and controls
in the eligible studies. There was no evidence of Hard-
Weinberg disequilibrium in both cases and controls.
Bias diagnostics
We did not find any evidence of publication bias of the
eligible studies. Funnel plots for the comparisons most
Odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for heterozygotes vs. C homozygotes Figure 9
Odds ratios of association between rs7903146 polymorphism of TCF7L2 gene and T2DM for heterozygotes vs. 
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commonly made, that is, for T allele vs. C allele, T
homozygotes (TT) vs. C homozygotes (CC), and hetero-
zygotes (TC) vs. C homozygotes (CC) are indicated in fig-
ure 1, 2 and 3. These three plots give corrected P = 0.410
(corrected z = 0.82), corrected P = 0.379 (corrected z =
0.88), and corrected P = 0.426 (corrected z = 0.80), respec-
tively. Figure 4, 5, and 6 indicate the cumulative meta-
analysis after each study from March 2006 to February
2008, for T allele vs. C allele, T homozygotes vs. C
homozygotes, and heterozygotes vs. C homozygotes. The
random-effects odds ratio of T homozygotes vs. C
homozygotes waved slightly among studies performed in
2006 and has changed very little from around 2.0 after the
eleventh study (figure 5). Cumulative meta-analysis of the
other two comparisons by year of publication showed
that the association between T2DM and TCF7L2 IVS3C>T
polymorphism has remained significant and been consist-
ent over time (figure 4 and figure 6).
Allele comparisons
Data from control groups were used for calculating the
summary allele frequency. The frequency of the risk allele
T at TCF7L2 gene among controls was 20.2 percent (95%
confidence interval (CI): 16.3, 24.1) and was considerable
variation in different ethnic populations (for Caucasians,
29.0% (95% CI: 28.3, 29.7); for North Europeans, 21.9%
(95% CI: 16.2, 27.6); for East Asians, 3.2 (95% CI: 2.6,
3.9); for Indians, 28.1% (95% CI: 25.9, 30.3); for others,
23.0% (95% CI: 9.4, 36.6)). We first contained all the 35
studies to evaluate the overall association between
TCF7L2  IVS3C>T polymorphism and T2DM. With our
allele-based analysis, the pooled odds ratio suggested a
1.416-fold increase in susceptibility to T2DM among per-
sons with the T allele (random-effects ORTvC = 1.416, 95%
CI: 1.346, 1.491), with a finding that was highly statisti-
cally significant (P  = 0.000), but there was significant
between-study heterogeneity (Q = 104.966, P = 0.000; I2
= 67.6%) (Table 6 [Additional file 1], figure 7).
Genotype comparisons
The genotype frequency of TCF7L2  IVS3C>T polymor-
phism between case and control groups is characterized in
web table. The genotype effects for TT versus CC (OR1)
and TC versus CC (OR2) were calculated for each study
Funnel plots of rs12255372 polymorphism studies for T allele vs. G allele (corrected z = 0.96, corrected P = 0.339) Figure 10
Funnel plots of rs12255372 polymorphism studies for T allele vs. G allele (corrected z = 0.96, corrected P = 
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(data are not shown and available from the first author on
request). In our primary concern, multivariate meta-anal-
ysis was conducted to estimate the pooled effects and
there was an significant increased risk of T2DM among
populations with both homozygous variant TT genotype
(Bayesian random-effect OR1 = 1.968, 95 percent credible
interval (CrI): 1.790, 2.157) and heterozygous variant TC
genotype (Bayesian random-effect OR2 = 1.406, 95 per-
cent CrI: 1.341, 1.476), with a "moderate" between-study
heterogeneity (Q = 66.102, P = 0.001, I2 = 48.6%, figure 8)
in the former and a "notable" between-study heterogene-
ity (Q = 84.028, P = 0.000, I2 = 59.5%, figure 9) in the lat-
ter. The estimated stochastic parameter λ1 was 0.504 (95
percent CrI: 0.461, 0.551), which suggested a codominant
genetic mode of action.
Examination of heterogeneity
Meta-regression was used to explore the source of hetero-
geneity and it was found that ethnicity was the only co-
variable associated with both lnOR1 (meta-regression beta
coefficient (β) = -0.0993, P = 0.002) and lnOR2 (β = -
0.0360, P = 0.002). We then did a subgroup analysis by
stratifying study samples into five ethnic groups, that is,
Caucasians (11 samples), North European (6 samples),
East Asian (9 samples), Indians (4 samples) and other
racial descent group (5 samples), and found that this strat-
ification can remove all the between-study heterogeneity
among North Europeans, East Asians and Indians for both
OR1 and OR2, rather than that among Caucasians and
other racial group (Table 6, Additional file 1). We then did
a further subgroup analysis of Caucasians by stratifying
them into French Caucasians versus other Caucasians and
extracted the studies with African populations for an inde-
pendent analysis, and found that such analyses can only
remove heterogeneity among these three populations for
OR1 rather than OR2 (Table 6, Additional file 1). The
pooled OR1 for six ethnic groups by descending ranking,
that is, French Caucasians, other Caucasians, North Euro-
peans, Africans, Indians, and East Asians, was
3.051(95%CrI: 2.039, 4.906), 1.989 (95%CrI: 1.807,
2.216), 1.944 (95%CrI: 1.639, 2.284), 1.802 (95%CrI:
1.292, 2.480), 1.669 (95%CrI: 1.373. 2.104), and 1.595
(95%CrI: 0.537, 2.653), respectively, and the pooled OR2
by descending ranking was 1.766 (95%CrI: 1.427, 2.278)
for French Caucasians, 1.696 (95%CrI:1.258, 2.242) for
Africans, 1.406 (95%CrI: 1.230, 1.617) for Indians, 1.357
Funnel plots of rs12255372 polymorphism studies for T homozygotes vs. G homozygotes (corrected z = 0.62, corrected P =  0.536) Figure 11
Funnel plots of rs12255372 polymorphism studies for T homozygotes vs. G homozygotes (corrected z = 0.62, 
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(95%CrI: 1.255, 1.474) for North Europeans, 1.352
(95%CrI: 1.160, 1.591) for East Asians, and 1.349
(95%CrI: 1.278, 1.431) for other Caucasians (Table 2,
Additional file 1). The estimated parameter λ1 by descend-
ing ranking was 0.981 (95 percent CrI: 0.759, 0.999) for
Africans, 0.676 (95 percent CrI: 0.452, 0.957) for Indians,
0.670 (95 percent CrI: 0.278, 0.995) for East Asians, 0.511
(95 percent CrI: 0.449, 0.578) for French Caucasians,
0.472 (95 percent CrI: 0.345, 0.624) for North Europeans,
and 0.436 (95 percent CrI: 0.366, 0.511) for other Cauca-
sians, which suggested codominant genetic mode of
action among these different ethnic populations except
for Africans where dominant mode of action was found.
Although BMI was not associated with both lnOR1 and
lnOR2 by separate meta-regression analysis, the significant
association was found when we evaluate it together with
ethnicity (for lnOR1, β = -0.0512, P = 0.038; for lnOR2, β
= -0.0311, P  = 0.004). In addition, some references
reported that BMI may interact with TCF7L2  gene to
increase the risk of T2MD. Therefore, we did a subgroup
analysis for BMI (normal (< 30.0 kg/m2) vs. abnormal (≥
30.0 kg/m2). However, such stratification cannot remove
heterogeneity for both lnOR1 (Q = 35.017, P = 0.006, I2 =
52.1%) and lnOR2 (Q = 28.046, P = 0.013, I2 = 50.0%).
The pooled OR1, OR2, and λ1 for populations with normal
BMI were 2.017 (95%CrI: 1.711, 2.347), 1.470 (95%CrI:
1.350, 1.609), and 0.554 (95%CrI: 0.481, 0.637), respec-
tively. The pooled OR1, OR2, and λ1 for populations with
abnormal BMI were 1.931 (95%CrI: 1.670, 2.213), 1.337
(95%CrI: 1.250, 1.431), and 0.441 (95%CrI: 0.387,
0.500), respectively. Logistic regression analysis indicated
that there was no significant difference between popula-
tions with normal and abnormal BMI for both lnOR1 (P =
0.855) and lnOR2 (P = 0.716).
IVS4G>T
Our searches identified 29 studies (totally 57,235 partici-
pants; 28,188 cases of T2DM, 29,047 controls) meeting
our inclusion criteria. All of these studies examined the
IVS4G>T polymorphism (Table 4, Additional file 1).
Allele and genotype data were available for all the cases
and controls in the eligible studies. There was no evidence
of Hard-Weinberg disequilibrium in both cases and con-
trols.
Funnel plots of rs12255372 polymorphism studies for heterozygotes vs. G homozygotes (corrected z = 0.77, corrected P =  0.442) Figure 12
Funnel plots of rs12255372 polymorphism studies for heterozygotes vs. G homozygotes (corrected z = 0.77, 
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Bias diagnostics
There was no evidence of small study bias and publication
bias for any comparisons. Funnel plots for the compari-
sons made for T allele vs. G allele, T homozygotes (TT) vs.
G homozygotes (GG), and heterozygotes (TG) vs. G
homozygotes are shown in figure 10, 11 and 12. These
three funnel plots give corrected P = 0.339 (corrected z =
0.96), corrected P = 0.536 (corrected z = 0.62), and cor-
rected P = 0.442 (corrected z = 0.77), respectively. Figure
13, 14 and 15 indicate the cumulative meta-analysis after
each study from March 2006 to February 2008, for allele-
based analysis and two genotype-based models of
IVS4G>T polymorphism. The random-effects odds ratio
of allele-based analysis was significant more than 1 and
changed very little from around 1.379 after the first study
(figure 13). The random-effects odds ratio of T homozy-
gotes vs. G homozygotes waved slightly among studies
performed in 2006 and has changed very little from
around 1.884 after the eleventh study (figure 14). Cumu-
lative meta-analysis of heterozygotes vs. G homozygotes
by year of publication showed that the association
between T2DM and TCF7L2 IVS4G>T polymorphism has
remained significant and been consistent over time (fig-
ure 15).
Allele comparisons
The frequency of the risk allele T at TCF7L2 gene among
controls was 18.0 percent (95% CI: 13.5, 22.5) and was
considerable variation in different ethnic populations (for
Caucasians, 27.9% (95% CI: 27.0, 28.9); for North Euro-
peans, 22.3% (95% CI: 12.6, 32.1); for East Asians, 2.1
(95% CI: 1.4, 2.7); and for Indians, 23.1% (95% CI: 17.8,
28.3)). We first contained all the 29 studies to evaluate the
overall association between TCF7L2 IVS4G>T polymor-
phism and T2DM. With our allele-based analysis, the
summary odds ratio suggested a 1.379-fold increase in
susceptibility to T2DM among persons with the T allele
(random-effects ORTvG = 1.379, 95% CI: 1.307, 1.454),
with a finding that was highly statistically significant (P =
0.000), but there was significant between-study heteroge-
neity (Q = 66.191, P = 0.000; I2 = 57.7%) (Table 6 [Addi-
tional file 1], figure 16).
Cumulative meta-analysis of the odds ratios of association between rs12255372 polymorphism of TCF7L2 gene and T2DM for  T allele vs. H allele Figure 13
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Genotype comparisons
The genotype frequency of TCF7L2  IVS4G>T polymor-
phism between case and control groups is characterized in
Table 4, Additional file 1. The genotype effects for TT ver-
sus GG (OR3) and TG versus GG (OR4) were calculated for
each study (data are not shown and available from the
first author on request). In our primary concern, multivar-
iate meta-analysis was conducted to estimate the pooled
effects and there was an significant increased risk of T2DM
among populations with both homozygous variant TT
genotype (Bayesian random-effect OR2 = 1.885, 95 per-
cent credible interval (CrI): 1.698, 2.088) and hetero-
zygous variant TG genotype (Bayesian random-effect OR4
= 1.360, 95 percent CrI: 1.291, 1.433), with a "moderate"
between-study heterogeneity both in the former (Q  =
46.515, P = 0.015, I2 = 39.8%, figure 17) and in the latter
(Q = 47.980, P = 0.011, I2 = 41.6%, figure 18). The esti-
mated stochastic parameter λ2 was 0.486 (95 percent CrI:
0.431, 0.545), which suggested a codominant genetic
mode of action.
Examination of heterogeneity
Meta-regression was used to explore the source of hetero-
geneity and it was found that ethnicity was the only co-
variable associated with both lnOR3 (β = -0.1083, P  =
0.005) and lnOR4 (β = -0.0418, P = 0.047). We then did a
subgroup analysis by stratifying study samples into five
racial descent groups, that is, Caucasians (9 samples),
North European (4 samples), East Asian (8 samples),
Indians (4 samples) and other racial descent group (4
samples), and found that this stratification can remove all
the between-study heterogeneity among North Europe-
ans, East Asians and Indians for both OR3 and OR4, rather
than that among Caucasians and other ethnic group
(Table 6, Additional file 1). We then extracted the studies
with other Caucasians (7 studies) for an independent
analysis, and found that such analysis can well-done
remove the heterogeneity among these studies for both
OR3 (Q = 8.407, P = 0.210, I2 = 28.6%) and OR4 (Q =
4.327, P = 0.633, I2 = 0.0%) (Table 6, Additional file 1).
We did not do a further analysis of other ethnic group
because of different origin of populations in these studies.
Cumulative meta-analysis of the odds ratios of association between rs12255372 polymorphism of TCF7L2 gene and T2DM for  T homozygotes vs. G homozygotes Figure 14
Cumulative meta-analysis of the odds ratios of association between rs12255372 polymorphism of TCF7L2 gene 
and T2DM for T homozygotes vs. G homozygotes.BMC Medical Genetics 2009, 10:15 http://www.biomedcentral.com/1471-2350/10/15
Page 16 of 25
(page number not for citation purposes)
The pooled OR3 for four ethnic groups (data of other eth-
nic group not shown for the heterogeneity of these stud-
ies) by descending ranking, that is, Caucasians, North
Europeans, East Asians and Indians, was 2.091 (95%CrI:
1.755, 2.528; for other Caucasians, OR3 = 1.860 (95%CrI:
1.672, 2.012)), 1.889 (95%CrI: 1.485, 2.412), 1.875
(95%CrI: 0.464~3.439), and 1.593 (95%CrI: 1.286,
2.086), respectively, and the pooled OR4 by descending
ranking was 1.569 (95%CrI: 1.304, 1.887) for East Asians,
1.413 (95%CrI: 1.299, 1.555; for other Caucasians, OR4 =
1.326 (95%CrI: 1.251, 1.412)) for Caucasians, 1.380
(95%CrI: 1.222, 1.569) for North Europeans, and 1.358
(95%CrI: 1.176, 1.579) for Indians (Table 6, Additional
file 1). The estimated parameter λ2 by descending ranking
was 0.744 (95 percent CrI: 0.341, 1.996) for East Asians,
0.657 (95 percent CrI: 0.403, 0.982) for Indians, 0.507
(95 percent CrI: 0.347, 0.748) for North Europeans, and
0.470 (95 percent CrI: 0.410, 0.534) for Caucasians (for
other Caucasians, λ2  = 0.455, 95 percent CrI: 0.376,
0.541), which suggested codominant genetic mode of
action among all these four ethnic populations.
Although BMI was not associated with both lnOR3 and
lnOR4 by separate meta-regression analysis, the significant
association was found when we evaluate it together with
racial descent (for lnOR3,  β = -0.0600, P  = 0.029; for
lnOR4, β = -0.0467, P = 0.000). In addition, some refer-
ences reported that BMI may interact with TCF7L2 gene to
increase the risk of T2MD. Therefore, we also did a sub-
group analysis for BMI in this polymorphism. However,
such stratification can remove few heterogeneity for both
lnOR3 (Q = 22.517, P = 0.084, I2 = 37.2%) and lnOR4 (Q
= 19.733, P = 0.042, I2 = 47.0%). The pooled OR3, OR4,
and  λ2  for populations with normal BMI were 1.795
(95%CrI: 1.480, 2.211), 1.397 (95%CrI: 1.254, 1.567),
and 0.572 (95%CrI: 0.448, 0.731), respectively. The
pooled OR3, OR4, and λ2 for populations with abnormal
BMI were 1.957 (95%CrI: 1.710, 2.210), 1.343 (95%CrI:
1.261, 1.429), and 0.442 (95%CrI: 0.377, 0.511), respec-
tively. Logistic regression analysis indicated that there was
no significant difference between populations with nor-
mal and abnormal BMI for both lnOR1 (P = 0.069) and
lnOR2 (P = 0.152).
Cumulative meta-analysis of the odds ratios of association between rs12255372 polymorphism of TCF7L2 gene and T2DM for  heterozygotes vs. G homozygotes Figure 15
Cumulative meta-analysis of the odds ratios of association between rs12255372 polymorphism of TCF7L2 gene 
and T2DM for heterozygotes vs. G homozygotes.BMC Medical Genetics 2009, 10:15 http://www.biomedcentral.com/1471-2350/10/15
Page 17 of 25
(page number not for citation purposes)
Other polymorphisms
The C allele of IVS3T>C polymorphism (10 studies with
15,718 participants (8,175 cases of T2DM, 7,543 con-
trols); random-effects ORCvT  = 1.323, 95% CI: 1.232,
1.419, P = 0.000; Q = 12.615, P = 0.181, I2 = 28.7 percent)
and the C allele of IVS4G>C polymorphism (15 studies
with 21,161 participants (11,260 cases of T2DM, 9,901
controls); random-effects ORCvG = 1.238, 95 percent CI:
1.153, 1.330, P = 0.000; Q = 20.968, P = 0.102, I2 = 33.2
percent) were significantly associated with T2DM (Table
6, Additional file 1). The pooled OR5, OR6, and λ3 for
IVS3T>C polymorphism were 1.771 (95%CrI: 1.525,
2.062), 1.292 (95%CrI: 1.199, 1.402), and 0.450
(95%CrI: 0.330, 0.598), respectively. The pooled OR7,
OR8, and λ4  for IVS4G>C polymorphism were 1.471
(95%CrI: 1.300, 1.706), 1.242 (95%CrI: 1.152, 1.355),
and 0.561(95%CrI: 0.393, 0.777), respectively. These all
suggested a codominant genetic mode of action among
such two polymorphisms. We did not find any evidence
of small sample bias and publication bias for any of the
studies (IVS3T>C polymorphism: for OR5, corrected z =
0.54, corrected P = 0.592; for OR6, corrected z = 1.43, cor-
rected P = 0.152; IVS4G>C polymorphism: for OR7, cor-
rected z = 0.40, corrected P = 0.692, for OR8, corrected z =
1.39, corrected P = 0.166), and cumulative meta-analysis
results for both allele-based and genotype-based analysis
of the above two polymorphisms were stable (data and




This is a large meta-analysis, including data from 25
papers involved in 36 genetic association studies with
exactly 35,843 cases of T2DM and 39,123 controls, care-
fully avoiding the double-counting of participants in the
study. The HuGE systematic review provides the most
recent and comprehensive evaluation of the association
between four TCF7L2 gene polymorphisms and suscepti-
bility to T2DM. We find that near 70,000 subjects (33,135
cases of T2DM and 36,316 controls) were from 35 studies
concerning the IVS3C>T polymorphism, and over 55,000
(28,188 cases of T2DM and 29,047 controls) subjects
were from 29 studies investigating the IVS4G>T polymor-
Odds ratios of association between rs12255372 polymorphism of TCF7L2 gene and T2DM for T allele vs. H allele Figure 16
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phism. These two variants were the main study focus on
the association between TCF7L2  gene polymorphisms
and susceptibility to T2DM.
On one hand, the results indicates notable associations
between two main TCF7L2 gene polymorphisms, namely,
IVS3C>T as well as IVS4G>T, and T2DM. The magnitudes
of this association were moderate, however, statistically
significant. Our primary analysis finds that among
IVS3C>T polymorphism, TC heterozygotes carry just over
a 1.4-fold increased risk of T2MD, and TT homozygous
variants carry near a 2.0-fold increase in T2MD risk when
compared with CC homozygotes, and that among
IVS4G>T polymorphism, TG heterozygotes carry near a
1.4-fold increased risk of T2MD, and TT homozygous var-
iants carry approximate a 1.9-fold increase in T2MD risk
when compared with GG homozygotes. Significant mag-
nitudes of genetic effect for heterozygotes of these two var-
iants were confirmed by the analysis on the pooled odds
ratios among different ethnic groups with slight differ-
ences except for East Asians where higher pooled odds
ratio was observed in IVS4G>T polymorphism when com-
pared with that of the other ethnic populations, and
genetic effect sizes for homozygotes of these two variants
were also strengthened by the analysis on the pooled odds
ratios among different ethnic groups including Cauca-
sians, North Europeans, Africans and Indians by showing
a small variation. However, we found that there was no
significant association between such two homozygotes
and disease among East Asians, and therefore, conflicting
results have appeared, in which studies on Chinese pro-
vided negative results [57,71], however, positive results
were observed among Japanese populations [61,62,82].
Our meta-analysis on 9 studies of IVS3C>T polymor-
phism and 7 studies of IVS4G>T polymorphism among
East Asians indicates a moderate statistical association
and shows that the heterozygous variants contributed all
the increased risk of T2MD among this population. This
distinct disparity may suggest different mechanism of
gene-disease between East Asians and other ethnic popu-
lation. Moreover, although less samples and subjects were
provided, the IVS3T>C and IVS4G>C polymorphisms are
also significantly associated with T2DM. We then suggest
that TCF7L2 is the most common susceptible gene for
T2DM among various ethnic groups in the world.
Odds ratios of association between rs12255372 polymorphism of TCF7L2 gene and T2DM for T homozygotes vs. G homozy- gotes Figure 17
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On the other hand, we made no assumptions about
genetic models and finds that the pooled odds ratios can
clearly fit a multiplicative model and the lambda (λ)
parameter can well-done indicate a codominant genetic
mode of action with tight CIs among all these four
TCF7L2  gene polymorphisms. We also explored the
genetic mode among different ethnic populations and
similar results were observed in Caucasians, North Euro-
peans, East Asians and Indians except for Africans, where
dominant genetic mode is suggested for IVS3C>T poly-
morphism. We cannot verify the genetic mode of action
for Africans in the other three polymorphisms due to few
studies. In addition, genetic mode of IVS3C>T variant
among Africans also need a further verification by more
studies. Even so, we nevertheless suggest a potential mul-
tiplicative genetic model for the four TCF7L2 gene poly-
morphisms.
The effect size of overall association between IVS3C>T var-
iant and T2MD is near to 1.42, which is lower than that in
a former meta-analysis about TCF7L2  and T2MD per-
formed by Cauchi et al [77], and larger than that in a
pooled analysis of three genome-wide association (GWA)
study [73,74,76]. we supplement some studies about East
Asians and Pima Indians [55,57,71,88] in which risk
homozygous variant TT was scanty, and excluded several
studies without genotype frequency data, which may
decrease the overall effect but provide a more comprehen-
sive understanding of the association. Even so, we cannot
find any significant difference of effect size between our
study with the former meta-analysis as well as the pooled
GWA studies. In addition, we computed the PAR of
TCF7L2 according to IVS3C>T variant and the PAR for the
combined genotypes TT and TC were 16.9, 23.2, 14.1, 2.5,
17.9, 27.0 for overall, Caucasians, North Europeans, East
Asians, Indians, and Africans, respectively, suggesting this
gene polymorphism may contribute near 1/5 of all T2MD
in the globe except for East Asians.
Our findings were based on some gene-association studies
and tens of thousands participants and were robust to
each of the planned sensitivity analyses used. We cannot
find any evidence of publication bias and small study bias
by funnel plots and cumulative meta-analysis, but, con-
Odds ratios of association between rs12255372 polymorphism of TCF7L2 gene and T2DM for heterozygotes vs. G homozy- gotes Figure 18
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siderable between-study heterogeneity was found.
Between-study heterogeneity may be due to differences in
sample selection (e.g., in age, sex, diagnosis, sample con-
tent, etc), or in methods (e.g., genotyping method), or it
may be due to real differences in populations (e.g., in
race), or in interactions with other risk factors (genetic or/
and environmental factors). The results of primary analy-
sis (genotype-based) on the four polymorphisms showed
statistically significant between-study heterogeneity for
both IVS3C>T polymorphism (OR1  and  OR2), and
IVS4G>C polymorphism (OR3 and OR4). In this Human
Genome Epidemiology review, we examined five poten-
tial sources of between-study heterogeneity for genotype-
based model by meta-regression and it was suggested that
ethnicity was the only co-variable associated with the four
ORs. In fact, more detailed manner of ethnic stratification,
namely, French Caucasians, other Caucasians, North
Europeans, East Asians, Indians, and Africans, can remove
near all the heterogeneity of studies about both IVS3C>T
and IVS4G>C polymorphisms for OR1  to  OR4. Study
results reported by several articles showed that BMI may
cooperate with the TCF7L2 gene to increase the risk of the
T2DM. However, disagreement of the results was pub-
lished by different researchers. Cauchi et al[59], Horiko-
shi et al [62] and Humphries et al [67] separated to
analyze the nonobese type 2 diabetic subjects (BMI<30
Kg/m2) and more higher allelic ORs or RRs were obtained
in IVS3C>T and IVS4G>C polymorphisms; whereas,
Miyake et al [82], Chandak et al[70], and Dahlgren et al
[104] found that there was a slight increase or no change
of odds ratio by adjustment of BMI. So we stratified the
studied by BMI (normal vs. abnormal) and found that sig-
nificant between-study heterogeneity nevertheless
appeared in all the two subgroups. Both studies on
IVS3C>T and IVS4G>C polymorphisms provided us for
the similar results. But, we found a significant association
when it was evaluated together with ethnicity. These
results, on the one hand, suggested that BMI may be a pos-
sible factor to impact on the effect of TCF7L2 gene on
T2DM by a indirect action; on the other hand, were diffi-
cult for us to explain the deep-seated reasons that how the
BMI influence the effect of TCF7L2  gene on T2DM
because we cannot gain the original data of BMI in each
article. This is a general limitation of meta-analysis. So we
hope the reasonable interpretation will be presented in
the subsequent studies. Although sex [56,63,68,71,105],
age of cases [63,68,71,105], drugs[106], constitu-
tion[64,69], and lifestyle [64,69,105] may regulate the
effects of TCF7L2 gene, we cannot test the effects of age,
sex, drugs and lifestyle on heterogeneity due to without
sufficient related data being used. In addition, the age of
the control NGT groups may be associated with the heter-
ogeneity and the young controls may develop diabetes at
a later date. However, there are also insufficient data.
Potential gene-gene and gene-environment interaction
T2DM seems to result from a complicated interplay of
genetic and environmental factors influencing a number
of intermediate traits of relevance to the diabetic pheno-
type (e.g., insulin secretion, insulin action, fat distribu-
tion, obesity). As a matter of fact, T2DM appears to be
composed of subtypes where genetic susceptibility is
strongly associated with environmental factors at one end
of the spectrum, and highly genetic forms at the other end.
Thus, there are several possible interactions between gene
and gene or between gene and environmental factors.
Recent years, a series of new loci in some genes have been
identified to contribute about 10~30% population attrib-
utable risk (PAR) of T2DM [73-76,107]. But, the overall
PAR seems to far less than the cumulative effect. So there
must be some potential interactions among genes. The
strongest known T2DM association (random-effects
ORTvC≈1.42) was recently mapped to the transcription fac-
tor TCF7L2, a gene that is a target of the Wnt signaling
pathway [50]. Whereafter, some other genes such as
HHEX, IDE, DKK3 and KIF11, which are also in the Wnt
signaling pathway [108-113] may have some interactions
with TCF7L2 on the risk of T2DM. Cauchi et al [59]found
that the expression of TCF7L2 gene was downregulated in
obese subjects developing T2DM and they then brought
forward a hypothesis of a potential interaction between
TCF7L2 and Calpain-10 by a supporting material [114]
that suggested that the Calpain system was involved in the
constitutive regulation of β-catenin signaling functions.
Wnt signaling has recently been shown to regulate pancre-
atic β-cell proliferation and the author suggested a possi-
ble interation between TCF7L2 gene and β-catenin gene
[115]. However, there is not any reported publication
about the interaction between TCF7L2  other related
genes. These hypothetical interactions and their specific
effects on T2DM, as well as functional analyses, will be
required to further elucidate the role of variation in
TCF7L2 in the pathogenesis of T2MD and very large sam-
ples are needed.
A variety of environmental factors can be implicated in
the phenotype of T2DM, such as obesity, hypertension,
bad lifestyle (smoking, drinking, high-energy diet), short
of exercise, malnutrition, and some drugs [116]. All the
above environmental factors may interact with the
TCF7L2 gene to influence T2DM. So far, few specific gene-
environment interactions have been described for TCF7L2
gene polymorphisms. Because obesity is a major determi-
nant of development of T2DM, most patients with T2DM
are obese when they develop diabetes, and obesity aggra-
vates the insulin resistance. BMI and waist circumstance
may become the main focus on attention of interactions,
particularly in studies of IVS3C>T and IVS4G>C polymor-
phism among T2DM. Cauchi and colleagues [117]BMC Medical Genetics 2009, 10:15 http://www.biomedcentral.com/1471-2350/10/15
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reported that IVS3C>T risk allele is more prevalent in non-
obese than in obese diabetics. Humphries et al [67] found
a statistically significant interaction between IVS3C>T as
well as IVS4G>C genotype and BMI. Wang et al [118] rep-
licated the result of Humphries et al. In succession, Hel-
gason et al [47] discovered that two haplotypes, that is,
HapA and HapBT2D had a interaction with BMI, and that
the former was associated with increased BMI, whereas
the latter was associated decreased BMI. Florez et al [106],
observed that another index of obesity, waist circum-
stance, showed a nominally significant interation with
both IVS3C>T and IVS4G>T in spite of no interaction
between BMI and genotype. In addition, plasma triglycer-
ide (TG) and C-reactive protein (CRP) have also been
found to interact with genotype of both IVS3C>T and
IVS4G>T [67]. These early findings suggestive of gene-
environment interactions with the different TCF7L2 gene
polymorphisms should be interpreted extremely cau-
tiously, however, and much larger and more detailed
studies are looked forward to substantiating such putative
interactions with appropriate power and rigor. Comple-
mentarily, Smoking and drinking were important risk fac-
tors to influence on T2DM and they can also interact with
genetic factor to increase the risk of this disease [116]. We
found a higher proportion of current or/and past smokers
and drinkers in the study populations. But, it was regret-
ted for us that there was no any report about the interac-
tions between TCF7L2 gene polymorphisms and smoking
or/and drinking in all the open publications. This is a
meaningful and valuable domain to explore.
Limitation of this meta-analysis
The lack of information especially the genotype data from
some articles was the main limitation, we have done our
possible to contact exhaustibly to the authors of publica-
tion that did not provide the original data and obtained
full data on about 75 percent of subjects involved in vari-
ous ethnic populations. Next, the quality of diagnosis,
match, and genotyping varied a lot among studies, but the
summary results were not changed when these questions
were discussed carefully. There was considerable heteroge-
neity in IVS3C>T and IVS4G>T polymorphisms in our ini-
tial results. However, we discovered the main sources of
the heterogeneity and were able to remove it finally. A
question we cannot resolve is that how the four snps dis-
cussed here in strong LD will lead to differences in T2DM
association among diverse populations. Besides, since
environment factors and genes, such as obesity, smoking,
drinking, and hypertension as well as plasma TG, and
gene related to the Wnt signaling pathway are strong can-
didates for a potential interaction with TCF7L2 gene pol-
ymorphisms, the lack of data available to us on most of
those environmental factors (except for obesity) and
genes was a limitation, which we hope will be demon-
strated by the following studies.
Conclusions and recommendation for future 
researches
This large meta-analysis summarizes the strong evidence
for an association between TCF7L2 gene and T2DM both
overall and in Caucasians, North Europeans, East Asians,
Indians, and Africans, and suggested a potential multipli-
cative genetic model for all the four polymorphisms of
TCF7L2 gene among different ethnic populations except
for Africans, where additive genetic mode is suggested for
IVS3C>T polymorphism. Our study results also suggest
that IVS3C>T and IVS4G>T variants of TCF7L2 gene can
be taken as reference loci for exploring T2DM susceptibil-
ity. We found and removed the main source of heteroge-
neity; however, we cannot find any evidence of bias.
Furthermore, we estimated the potential gene-gene and
gene-environmental interactions by which common vari-
ants in the TCF7L2 gene influence risk of T2DM. These
two domains are just the recommendation for future
researches.
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